Skip to main content

Fiscal Wizard · Single-issue tearsheet

TECH / Oct 1, 2026 Run #19122
Paper trade

TECH

Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Composite verdict

B 67.7 / 100
Bullish setup · Directional State 5 drivers · 3 gates blocking
  • Engulfing
  • 52-Week Proximity
  • ADX DI Cross
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 7th of 21 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 16 signals0% Bear
Momentum Bullish 98Mean-reversion Neutral 50
  • Late-stage trendTrend signals have been live for 68 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -79%
Asset value $13.44Earnings power value $13.90Price $72.44

Priced above its no-growth earnings power value ($13.90/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

37.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Capex to Sales 65
OCF to Net Income 0
Cash Conversion 0

Technicals Bullish

98.5 / 100

Bullish setup leads (Engulfing, 52-Week Proximity, ADX DI Cross); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Engulfing 77
52-Week Proximity 65
ADX DI Cross 65

Risk Gates

3 blocking 6 caution

3 guards active, 26 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for TECH.